Small Pharma Inc (OP:DMTTF)

N/A UNCHANGED

Last Price Updated: 3:59 PM EDT, Oct 20, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Small Pharma Inc

< Previous 1 2 3 4 5 6 7 Next >

Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD ↗

January 06, 2024

A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub

Via Benzinga

Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoirs And More ↗

October 29, 2023

Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted

Via Benzinga

Topics Intellectual Property

Cybin's Deuterated Psychedelics Programs Protected By Three New International Patents ↗

October 26, 2023

Cybin’s (NYSE: CYBN) deuterated psychedelics programs received two patent grants from the United States Patent and Trademark Office (USPTO,) and one from the European Patent Office (EP.)

Via Benzinga

Topics Intellectual Property

Cybin Officially Owns Small Pharma: Plans For New 'International Leader' In Psychedelic Therapeutics ↗

October 23, 2023

Psychedelics companies Cybin Inc. (NYSE: CYBN) and Small Pharma Inc. (OTCQB: DMTTF) have completed their August acquisition agreement.

Via Benzinga

Psyched: Jada Pinkett-Smith's Ayahuasca Journey, RIP Dr. Roland Griffiths, Congressional VA Hearings Halted ↗

October 22, 2023

Jada Pinkett Smith Opens Up About Ayahuasca: It Helped Her Overcome Depression And Suicidal Thoughts

Via Benzinga

Small Pharma's Q2 2024 Financial Highlights Ahead Of Cybin Merger For Global DMT Business ↗

October 20, 2023

Small Pharma Inc. (OTCQB: DMTTF), the short-acting psychedelics biotech about to be purchased by Cybin Inc.

Via Benzinga

Moving Closer To Cybin Acquisition, Small Pharma Obtains Final Order Approving Arrangement ↗

October 18, 2023

Short-acting psychedelics biotech Small Pharma Inc.

Via Benzinga

Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More ↗

October 16, 2023

Cybin And Small Pharma Shareholders Green Light Acquisition Resolution

Via Benzinga

Cybin And Small Pharma Shareholders Green Light Acquisition Resolution: Results & Expected Dates ↗

October 13, 2023

Clinical-stage psychedelics biotechs Canada-based Cybin Inc. (NYSE: CYBN) and UK-based Small Pharma Inc.

Via Benzinga

Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More ↗

October 02, 2023

Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of...

Via Benzinga

Depression Relief: Possible Therapy Boost With DMT & SSRIs, Per Small Pharma Clinical Results ↗

September 26, 2023

New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of psychedelics and traditional pharma for the treatment of major depressive disorder (MDD) are out.

Via Benzinga

Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More ↗

September 26, 2023

Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge

Via Benzinga

Topics Economy

Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression ↗

September 21, 2023

Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive...

Via Benzinga

Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R&D, Blake Mycoskie's $100M Pledge Update ↗

September 18, 2023

Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly $19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN).

Via Benzinga

Cybin's Intellectual Powerhouse Grows With New US Patent Covering Deuterated 5-MeO-DMT ↗

September 05, 2023

The U.S. Patent and Trademark Office (USPTO) has granted Canada-based psychedelics company Cybin Inc. (NYSE: CYBN) a new patent covering the composition of matter of deuterated 5-MeO-DMT analogs and...

Via Benzinga

Topics Intellectual Property

Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More ↗

September 05, 2023

Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety

Via Benzinga

Mindset Pharma's $60M Acquisition, Otsuka's Leap Into Next-Gen Psychiatry Solutions ↗

August 31, 2023

Canadian next-generation psychedelics developer Mindset Pharma (OTCMKTS: MSSTF) has entered into a definitive agreement to acquire all outstanding shares of Otsuka America Inc. the U.S. arm of Otsuka...

Via Benzinga

Second Psychedelics Merger Of The Week? Silo Wellness To Buy Jamaica-Based Business For $31.9M ↗

August 29, 2023

Silo Wellness (OTCQB: SILFF) has confirmed its intention to acquire all issued and outstanding securities of NUGL Inc./Kaya Group (OTC Pink: NUGL) in an arms-length transaction valued at $31.9...

Via Benzinga

Cybin's Acquisition Of Small Pharma Will Elevate DMT Therapeutics For Depression And Anxiety ↗

August 28, 2023

Psychedelics biotech Cybin (NYSE: CYBN) company and UK-based Small Pharma (OTCQB: DMTTF) announced their definitive arrangement agreement for Cybin’s acquisition of all Small Pharma’s issued and o

Via Benzinga

Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More ↗

August 03, 2023

A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances...

Via Benzinga

Small Pharma's Q1 2024: Revamping Strategy And Potential Fast-Tracked Clinical Trial ↗

July 28, 2023

UK’s short-acting psychedelics developer Small Pharma (OTCQB: DMTTF) published its financial results for the fiscal first quarter ended May 31, 2023:

Via Benzinga

Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More ↗

July 11, 2023

First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic...

Via Benzinga

Small Pharma Implements Costs Cut: New R&D Strategy And Management Team Change ↗

July 05, 2023

Together with reporting its annual financial results and pipeline update, short-acting psychedelics developer Small Pharma Inc. (OTCQB: DMTTF) stated its intentions to

Via Benzinga

Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More ↗

July 04, 2023

World's Largest Psychedelics Conference Boasts 12K Attendees

Via Benzinga

Small Pharma Implements Cost-Cutting Strategy To Reduce Cash Burn As Trial Progresses ↗

June 29, 2023

UK-based biotech firm Small Pharma Inc. (OTCQB: DMTTF) shared its financial outcomes for the fiscal year ended Feb. 28, plus pipeline updates. Highlights:

Via Benzinga

Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More ↗

May 31, 2023

Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics...

Via Benzinga

Small Pharma's IP Portfolio Grows With Numerous Approved Patent Applications Around The World ↗

May 26, 2023

U.K.-based short-acting psychedelics developer Small Pharma Inc. (OTCQB: DMTTF) has been working hard on securing a proprietary IP throughout North America, Australasia and Europe.

Via Benzinga

DMT For Major Depression Shows Remarkable Benefits After Six-Month Trial ↗

April 04, 2023

Short-acting psychedelics company Small Pharma Inc.

Via Benzinga

EXCLUSIVE: NYC Ketamine Center Co-Founder On Prices, Insurance, Competition & Expansion ↗

March 21, 2023

This is the third article of a three-part series, you can find the first and

Via Benzinga

Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More ↗

March 13, 2023

Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.